Alvíz-Amador A, Moreno-Babilonia L, Tulcan-Canchala KM, Contreras-Puentes N, Gómez-Castillo LE, Ramos-Clason E

Language: Spanish
References: 14
Page: 1-15
PDF size: 369.25 Kb.

ABSTRACT

Introduction: The crisis caused during the COVID-19 pandemic led scientists around the world to think about the creation of different vaccines against SARS-CoV-2. One of them was the inactivated virus vaccine CoronaVac, which was approved by Colombia's Ministry of Health. However, there are few pharmacovigilance studies conducted by occupational medicine to know the adverse events caused by vaccines.
vObjective: To estimate the safety of the CoronaVac vaccine.
Methodology: Descriptive, retrospective and quantitative study, in which a population group of 508 workers from the port of Cartagena group was chosen, who were selected under inclusion criteria, during the second period of 2021 and the first of 2022.
Results: 3.54 % of workers reported adverse events within the study population. Men had the most reports with 72.2% and women 27.8%. The most affected population group in terms of age was those aged 30 to 35 years, with a report of 44.4%. Likewise, the systems where there was a higher percentage of reports were the musculoskeletal, respiratory, and nervous system for first, second and third doses respectively; with symptoms such as headache, malaise, fever, muscle and joint pain, followed by pain in the injection area.
Conclusions: In this study it was possible to identify the adverse events reported by the study population. However, none of the events presented had a serious or negative influence on the health and integrity of the workers during the study period. In this way, the safety of the vaccine was estimated. It should be noted that the CoronaVac vaccine did not prevent the spread or possible reinfection of the virus.

REFERENCES

1. Baraniuk C. Covid-19: How effective are vaccines against the delta variant? BMJ. 2021;374:12-13. DOI: 10.1136/bmj.n1960.

2. Galván C, Català A, Carretero G, Rodríguez P, Fernández D, Rodríguez A, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br. J. Dermatol. 2020;183(1):71-7. DOI: 10.1111/bjd.19163.

3. Bahouq H, Bahouq M, Soulaymani A, Soulaymani R. Pharmacovigilance in Covid-19 vaccines. Medicine. E3S Web Conf. 319. 2021. DOI: 10.1051/e3sconf%2F202131901012.

4. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 1981;30(2):239-45. DOI: 10.1038/clpt.1981.154.

5. Pubmed.gov.. Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury. Estados Unidos de América; National Library of Medicine. 2012 [acceso 11/09/2020]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31689026/

6. MINSALUD. Manual de farmacovigilancia de medicamentos Monopolio del Estado. Bogotá: Ministerio de Salud y Protección Social. 2019 [acceso 24/09/2020]. Disponible en: https://www.minsalud.gov.co/salud/MT/Paginas/gestion-de-operaciones-nacionales.aspx

7. Riad A, Sağıroğlu D, Üstün B, Pokorná A, Klugarová J, Attia S, et al. Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey. J. Clin. Med. 2021;10(12). DOI: 10.3390/jcm10122629.

8. Kaya F, Pirincci E. Determining the frequency of serious adverse reactions of inactive SARS-COV-2 vaccine. Work. 2021;69(3):735-39. DOI: 10.3233/WOR-210473.

9. INVIMA. Boletín #11: Vigilancia de Eventos Adversos Posteriores a la Vacunación (EAPV) contra COVID-19 en Colombia. Bogotá: Minsalud; 2022 [acceso 23/09/2022], p. 2-4. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/boletin11-farmacovigilancia-vacunas-mar2022.pdf

10. Ministerio de Salud Gobierno de Chile. Octavo Informe Estadístico ESAVI asociado a la administración de vacunas SARS-CoV-2 en Chile en personas desde los 18 años. Santiago de Chile. Chile: Insttuti de Salud Pública. 2022 [acceso 15/10/2022].Disponible en: https://www.ispch.cl/wp-content/uploads/2022/03/8°Informe-estadistico-poblacion-mayor-de-18-anos-VF.pdf

11. Wilbur Chen. Vacuna COVID: ¿Por qué los jóvenes sufren peores efectos secundarios de la vacuna?: Universidad de Maryland. Facultad de Medicina; 2021 [acceso 23-03-2022]. Disponible en: https://www.medschool.umaryland.edu/news/2021/Dr-Wilbur-Chen-Nationally-Recognized-Vaccine-Researcher-Selected-for-Federal-Committee-that-Guides-Immunization-Policies.html

12. Chuaychoosakoon Ch, Parinyakhup W, Tanutit P, Maliwankul K, Klabklay P. Lesión de hombro relacionada con la vacuna Sinovac COVID-19: Reporte de un caso. Annals of Medicine and Surgery. 2021;68:1-3. DOI: 10.1016/j.amsu.2021.102622.

13. Bencharattanaphakhi R, Rerknimitr P. Vasculitis leucocitoclástica cutánea inducida por la vacuna Sinovac COVID-19. JAAD Case Reports. 2021;18:1-3. DOI: 10.1016/j.jdcr.2021.10.002.

14. Vega VM. Informe Técnico: Revisión de Transtornos menstruales y vacunación COVID-19. Santiago de Chile: Instituto de Salud Pública Gobierno de Chile; 2021 [acceso 28/04/2022] p.5-6. Disponible en: https://www.ispch.cl/wp-content/uploads/2021/11/Informe-tecnico-SDFV-N°-56-Vacunas-Covid-y-tranastornos-menstruales-VF-1.pdf